After Hours Summary: STX +12.5% and AA +3.7% on earnings/guidance... IMPV -9.7% after cutting guidance, TSLA -1.2% on potential SEC investigationAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: NEPT +13.7% (thinly traded), STX +12.5%, AA +3.7%(also Cube Hydro Carolinas reaches agreement to acquire hydroelectric plants from Alcoa Power Generating)
Companies trading higher in after hours in reaction to news: JRJR +13.6% (compliance plan was accepted by NYSE MKT relating to failure to timely file its Quarterly Report on Form 10-Q), CASC +11.4% (Growth Equity Opportunities Fund discloses 8.3% active stake), BDSI +11.2% (secured preferred formulary status for BUNAVAIL on a 'significant' managed care plan), BAA +7% (reports Q2 operating results), RRD +6.9% and XRX +2.6% (reports of RR Donnelley & Sons potential merger with Xerox's Copy unit), MGT +5% (following late pullback -- released prelim proxy statement), WDC +4.4% and NTAP +0.2% (on STX guidance), CLDX +3.1% (initiates Phase 1/2 clinical trial of new product candidate CDX-014 in advanced renal cell carcinoma), RLYP +2.5% (discloses new patient starts, outpatient prescriptions and units sold to hospitals/other institutions for June), HUM +1.6% (following late decline amid continued merger concerns), REN +1.5% (following 60% move higher today; also John C. Goff increases active stake to 9.9%), NTIP +1.4% (discloses settlement of patent litigation with Alcatel-Lucent Entities and ALE), UAL +1.1% (reported June 2016 operational results; expects Q2 passenger unit revenue to decline 6.50% to 6.75% YoY, citing several headwinds)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: IMPV -9.7% (lowers Q2 guidance citing impacts by extended sales cycles across most geographies and verticals predominantly relating to larger deals)
Companies trading lower in after hours in reaction to news: CYTR -64.9% (announces results of an analysis of its Phase 3 clinical trial of aldoxorubicin compared to investigator's choice therapy in patients with relapsed or refractory soft tissue sarcomas; study did not show a significant difference between aldoxorubicin and investigator's choice therapy for PFS), BLFS -3% (following 50%+ move higher today), ALR -2.4% (Alere to initiate voluntary withdrawal of the Alere INRatio and INRatio 2 PT/INR monitoring system), CHRS -1.3% (after closing near highs -- up 25% on the day), TSLA -1.2% (WSJ reported potential SEC investigation)
Select IMPV peers tradng lower in sympathy: FTNT -1.7%, PANW -1.6%, SPLK -0.3%, FEYE -0.2